Trials / Withdrawn
WithdrawnNCT02812862
Cardiac Effects of Spiolto®/Respimat® in Patients With Congestive Heart Failure and COPD
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- RWTH Aachen University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the pulmonary and cardiac effects of the LABA / LAMA combination Tiotropium / Olodaterol therapy in patients suffering from both congestive heart failure and chronic obstructive pulmonary disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Spiolto® Respimat® (Tiotropium / Olodaterol) | LABA/ LAMA combination therapy: A combination of two bronchodilators acting on two separate pharmacological targets - one ß-agonist and one anti-muscarinergic agent. |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2017-08-01
- Completion
- 2018-08-01
- First posted
- 2016-06-24
- Last updated
- 2022-10-27
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02812862. Inclusion in this directory is not an endorsement.